News
Market and company headlines
RZLTAll
Loading
12:00Oct 141 Story
04:00-13:00Oct 62 Stories
Lake Street Maintains Buy on Rezolute, Raises Price Target to $12
Lake Street analyst Daniel Brims maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $9 to $12.
Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $15
Citizens analyst Jason N. Butler maintains Rezolute (NASDAQ:RZLT) with a Market Outperform and raises the price target from $11 to $15.
02:00Oct 61 Story
08:00Oct 52 Stories
Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’
The U.S. Food and Drug Administration recommended that the company request a Type B pre-BLA meeting for Ersodetug in congenital hyperinsulinism
Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment
Rezolute (RZLT) said Monday that the US Food and Drug Administration has recommended a meeting befor
07:00Oct 51 Story
08:00Sep 301 Story
04:00-07:00Sep 292 Stories
This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded STAA, NFLX, SFIX, with ratings moving toward Buy or Neutral and mixed price-target changes.
Craig-Hallum Upgrades Rezolute to Buy, Raises Price Target to $7
Craig-Hallum analyst Albert Lowe upgrades Rezolute (NASDAQ:RZLT) from Hold to Buy and raises the price target from $4 to $7.
02:00Sep 281 Story
08:00Sep 251 Story
12:00-17:00Sep 242 Stories
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026. Tumor HI upLIFT, a Phase 3, single-arm, open label study in up to 16 hospitalized participants for the treatment of tumo
Rezolute Q4 EPS $(0.20) Misses $(0.15) Estimate
Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.15) by 33.33 percent. This is a 23.08 percent increase over losses of $(0.26) per share from the
09:00Sep 101 Story
13:00-16:00Sep 92 Stories
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks were lower late Wednesday afternoon with the NYSE Healthcare Index and the State S
Sector Update: Healthcare Stocks Decline in Afternoon Trading
Healthcare stocks were lower Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and the S
07:00-11:00Sep 92 Stories
Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint
Rezolute (NASDAQ:RZLT) said the FDA is continuing its review of additional Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism after the study failed to meet its primary endpoint, leaving the potential regulatory path unresolved and without a specific timeline for agency feedback. Key Investor TakeawaysThe FDA review remains ongoing as the agency evaluates whether there is a potential regulatory path forward for ersodetug in congenital hyperinsulinism.
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in the use of background standard of care therapies Enrollment continues in the Phase 3 upLIFT study in tumor HI and the Company remains on track to report topline results before the end of 2026 REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (